AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16634855 — intervention group
Group type: COMPARATOR
Intervention: Daily naltrexone (50 mg/day)
Number of subjects: 150
Study 16634855 — intervention group
Group type: COMPARATOR
Intervention: Targeted placebo
Number of subjects: 150
Study 16634855 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo
Number of subjects: 150
Study 12383892 — intervention group
Group type: EXPERIMENTAL
Intervention: New localization device
Number of subjects: 120
Study 12383892 — intervention group
Group type: COMPARATOR
Intervention: Traditional flexible wires
Number of subjects: 120
Study 9882027 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 195
Study 9882027 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily for 8 weeks)
Number of subjects: 195
Study 8014510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (2g)
Number of subjects: 61
Study 8014510 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (2g)
Number of subjects: 61
Study 2524679 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 31
Study 2524679 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 31
Study 1097035 — intervention group
Group type: EXPERIMENTAL
Intervention: L-histidine 4 g/day
Number of subjects: 42
Study 1097035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31490397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound added to conventional physiotherapy
Number of subjects: 0
Study 31490397 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study 28619227 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 161
Study 28619227 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 161
Study 28619227 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel
Number of subjects: 161
Study 28619227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 24071051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy guided caudal epidural steroid injection (CESI)
Number of subjects: 46
Study 24071051 — intervention group
Group type: COMPARATOR
Intervention: Oral non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 46
Study 21881324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (0.2 mg/kg/h until weaning from mechanical ventilation)
Number of subjects: 22
Study 21881324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sivelestat sodium hydrate)
Number of subjects: 22
Study 21881324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Number of subjects: 22
Study 21881324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 18688631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral crural steal (LCS) along with placement of a columellar strut and transdomal sutures
Number of subjects: 60
Study 18688631 — intervention group
Group type: COMPARATOR
Intervention: Standard techniques (narrowing transdomal sutures and placing a columellar strut) without LCS
Number of subjects: 60
Study 17270624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 154
Study 17270624 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154
Study 17270624 — intervention group
Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 154
Study 17270624 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 154
Study 15505447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium infusion
Number of subjects: 23
Study 15505447 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium infusion
Number of subjects: 23
Study 15505447 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium and Vecuronium
Number of subjects: 23
Study 11272721 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP A vaccine (25 units in 0.5 mL)
Number of subjects: 105
Study 11272721 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP A & B vaccines concurrently (HEP A: 25 units in 0.5 mL; HEP B: 10 micrograms in 1.0 mL)
Number of subjects: 105
Study 11272721 — intervention group
Group type: COMPARATOR
Intervention: HEP B vaccine (10 micrograms in 1.0 mL)
Number of subjects: 105
Study 9517592 — intervention group
Group type: COMPARATOR
Intervention: Inhaled NO concentration of 20 ppb
Number of subjects: 10
Study 9517592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NO concentrations of 49 ppb, 98 ppb, and 148 ppb
Number of subjects: 10
Study 8052381 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional rhizotomy from L2-S2 including S2 rootlets
Number of subjects: 85
Study 8052381 — intervention group
Group type: COMPARATOR
Intervention: Functional rhizotomy from L2-S1 excluding S2 rootlets
Number of subjects: 85
Study 2488113 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL) 180-240 mg
Number of subjects: 39
Study 2488113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PDL) 15-45 mg
Number of subjects: 39
Study 769949 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cyclophosphamide (3 mg/kg/day)
Number of subjects: 151
Study 769949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose cyclophosphamide (10 mg/kg/day for 4 days out of 14)
Number of subjects: 151
Study 769949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (3 mg/kg/day) plus cytosine arabinoside (3 mg/kg/week im)
Number of subjects: 151
Study 31764989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulphate (NaTS) 25 g/1.73 m2
Number of subjects: 60
Study 31764989 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 60
Study 31169558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological diagnosis of MPM from pleural fluid
Number of subjects: 0
Study 31169558 — intervention group
Group type: EXPERIMENTAL
Intervention: BAP1 immunostaining and CDKN2A/p16 fluorescence in‐situ hybridization
Number of subjects: 0
Study 31169558 — intervention group
Group type: COMPARATOR
Intervention: Routine use of prophylactic radiotherapy after pleural interventions
Number of subjects: 0
Study 28946535 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 40
Study 28946535 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (KIN)
Number of subjects: 40
Study 25771819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% SF 6 gas (group 1)
Number of subjects: 45
Study 25771819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% SF 6 gas (group 2)
Number of subjects: 45
Study 25771819 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil (group 3)
Number of subjects: 45
Study 25771819 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control) for group 1
Number of subjects: 45
Study 25771819 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control) for group 2
Number of subjects: 45
Study 25771819 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control) for group 3
Number of subjects: 45
Study 23684157 — intervention group
Group type: EXPERIMENTAL
Intervention: No PPM
Number of subjects: 266
Study 23684157 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PPM
Number of subjects: 266
Study 23684157 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe PPM
Number of subjects: 266
Study 23684157 — intervention group
Group type: COMPARATOR
Intervention: PPM (overall)
Number of subjects: 266
Study 21802630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine group (n = 40) received 4.5 mL of lidocaine‐bupivacaine and 0.5 μg/kg of clonidine in a 0.5 mL volume
Number of subjects: 80
Study 21802630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40) received a retrobulbar block with 4.5 mL of lidocaine‐bupivacaine and 0.5 mL of saline
Number of subjects: 80
Study 21802630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 21802630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 80
Study 19567926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined uphill-downhill (U+D) training
Number of subjects: 54
Study 19567926 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal (H) training
Number of subjects: 54
Study 19567926 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 54
Study 16877955 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (Nt-proBNP)
Number of subjects: 945
Study 16877955 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 945
Study 16647884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine monotherapy (mean daily dose 19.7 mg/day, range 5-35 mg/day)
Number of subjects: 34
Study 16647884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine monotherapy
Number of subjects: 34
Study 12966416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin hydrochloride
Number of subjects: 0
Study 12966416 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 0
Study 10078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 10 days
Number of subjects: 18
Study 8542742 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients without complications
Number of subjects: 110
Study 8542742 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with microvascular disease
Number of subjects: 110
Study 8542742 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients
Number of subjects: 110
Study 8542742 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 110
Study 2318912 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized information presentation
Number of subjects: 0
Study 2318912 — intervention group
Group type: COMPARATOR
Intervention: Less-organized information presentation
Number of subjects: 0
Study 628364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapotum D minor
Number of subjects: 30
Study 628364 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 31184752 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 295
Study 31184752 — intervention group
Group type: COMPARATOR
Intervention: US-RTX
Number of subjects: 295
Study 31184752 — intervention group
Group type: EXPERIMENTAL
Intervention: US-RTX/CT-P10
Number of subjects: 295
Study 31184752 — intervention group
Group type: EXPERIMENTAL
Intervention: EU-RTX/CT-P10
Number of subjects: 295
Study 31184752 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 295
Study 27555447 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses with medial arch support and lateral wedge insoles (6° and 10° inclination)
Number of subjects: 18
Study 27555447 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthoses without lateral inclination
Number of subjects: 18
Study 27555447 — intervention group
Group type: COMPARATOR
Intervention: Foot orthoses without any additional support
Number of subjects: 18
Study 27555447 — intervention group
Group type: COMPARATOR
Intervention: Foot orthoses with medial arch support
Number of subjects: 18
Study 26056105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent anti-tuberculosis treatment (thrice weekly)
Number of subjects: 0
Study 26056105 — intervention group
Group type: COMPARATOR
Intervention: Daily anti-tuberculosis treatment
Number of subjects: 0
Study 24000010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 50
Study 24000010 — intervention group
Group type: COMPARATOR
Intervention: Healthy Nutritional Recommendations (HNR) diet
Number of subjects: 50
Study 21512411 — intervention group
Group type: EXPERIMENTAL
Intervention: EBTM group (Esomeprazole, Bismuth subcitrate, Tetracycline, Metronidazole)
Number of subjects: 120
Study 21512411 — intervention group
Group type: EXPERIMENTAL
Intervention: EBTA group (Esomeprazole, Bismuth subcitrate, Tetracycline, Amoxicillin)
Number of subjects: 120
Study 21512411 — intervention group
Group type: EXPERIMENTAL
Intervention: EBTM group
Number of subjects: 120
Study 21512411 — intervention group
Group type: EXPERIMENTAL
Intervention: EBTA group
Number of subjects: 120
Study 21512411 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 21512411 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-resistant strains
Number of subjects: 120
Study 19303891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (H2S) at low concentration (2 ppm)
Number of subjects: 0
Study 19303891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (H2S) at high concentration (8 ppm)
Number of subjects: 0
Study 19303891 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoamyl acetate (IAA) at 17.5%
Number of subjects: 0
Study 19303891 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) at 50% v/v
Number of subjects: 0
Study 17130343 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/d
Number of subjects: 0
Study 17130343 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 0
Study 17130343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17130343 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 1000 mg
Number of subjects: 0
Study 17130343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 0
Study 17130343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 0
Study 15311720 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE + ATV 10 mg
Number of subjects: 246
Study 15311720 — intervention group
Group type: COMPARATOR
Intervention: ATV 10 mg
Number of subjects: 246
Study 11163469 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pneumococcal conjugate vaccination program
Number of subjects: 3800000
Study 9067720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sillix Donna (active preparation)
Number of subjects: 40
Study 9067720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8336748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (100-200 micrograms/day)
Number of subjects: 18
Study 8336748 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms/day)
Number of subjects: 18
Study 8336748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (2.5 to 7.5 mg/day)
Number of subjects: 18
Study 2946313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl
Number of subjects: 19
Study 2946313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of alfentanil
Number of subjects: 19
Study 2946313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl and alfentanil
Number of subjects: 19
Study 31655134 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks with simplified monitoring
Number of subjects: 380
Study 31655134 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring with glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks
Number of subjects: 380
Study 31556670 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT)
Number of subjects: 785
Study 31556670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) alone
Number of subjects: 785
Study 31556670 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU; 12-step facilitation, supportive therapy)
Number of subjects: 785
Study 31556670 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 785
Study 31556670 — intervention group
Group type: COMPARATOR
Intervention: A-CRA
Number of subjects: 785
Study 28586233 — intervention group
Group type: EXPERIMENTAL
Intervention: DentalVibe® Injection Comfort System (DV3)
Number of subjects: 60
Study 28586233 — intervention group
Group type: COMPARATOR
Intervention: Control (no DV3)
Number of subjects: 60
Study 25481382 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal coaching, tailored information, and materials (intervention group)
Number of subjects: 314
Study 25481382 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 314
Study 23458449 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete steroids avoidance (n = 50)
Number of subjects: 100
Study 23458449 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 50)
Number of subjects: 100
Study 21272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake in GSTM1+ individuals
Number of subjects: 0
Study 21272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake
Number of subjects: 0
Study 21272319 — intervention group
Group type: COMPARATOR
Intervention: Control diet (fruit- and vegetable-free basal diet)
Number of subjects: 0
Study 19329003 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral azithromycin distributed four times per year to children aged 1-10 years
Number of subjects: 10778
Study 19329003 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed treatment until after the study)
Number of subjects: 10778
Study 16505178 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (25 to 200 mg daily)
Number of subjects: 208
Study 16505178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 14628279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (500 mg bid) plus didanosine (400 mg qd)
Number of subjects: 187
Study 11141512 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch, Discover, Think and Act (WDTA) educational program
Number of subjects: 76
Study 11141512 — intervention group
Group type: COMPARATOR
Intervention: Control group (children not using the program)
Number of subjects: 76
Study 9714028 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-buffered epoetin alpha
Number of subjects: 0
Study 9714028 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered epoetin alpha
Number of subjects: 0
Study 8296752 — intervention group
Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 104
Study 8296752 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 104
Study 2805810 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent
Number of subjects: 0
Study 2805810 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 1 percent
Number of subjects: 0
Study 2805810 — intervention group
Group type: COMPARATOR
Intervention: Econazole nitrate cream 1 percent
Number of subjects: 0
Study 2805810 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream 1 percent
Number of subjects: 0
Study 31515250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PEG) therapy
Number of subjects: 115
Study 28622317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy (DCR)
Number of subjects: 134
Study 28622317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid tightening
Number of subjects: 134
Study 28622317 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctoplasty
Number of subjects: 134
Study 28622317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (lid tightening plus punctoplasty)
Number of subjects: 134
Study 25939019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 3245
Study 25939019 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 3245
Study 25939019 — intervention group
Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 3245
Study 25939019 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3245
Study 22976131 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7 regimen (group 1)
Number of subjects: 21
Study 22976131 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/2 placebo/5 ethinyl estradiol 10 μg regimen (group 2)
Number of subjects: 21
Study 22044609 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational brief intervention group
Number of subjects: 1115
Study 22044609 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms group
Number of subjects: 1115
Study 22044609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1115
Study 19775434 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 37
Study 19775434 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (UC) + Manual Therapy (MT)
Number of subjects: 37
Study 17119521 — intervention group
Group type: COMPARATOR
Intervention: Walking on land (WL)
Number of subjects: 38
Study 17119521 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming (SW)
Number of subjects: 38
Study 17119521 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in water (WW)
Number of subjects: 38
Study 15010034 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 148
Study 15010034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill
Number of subjects: 148
Study 15010034 — intervention group
Group type: COMPARATOR
Intervention: Control (normal menstruating girls)
Number of subjects: 148
Study 10653925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive cholesterol-lowering therapy with atorvastatin
Number of subjects: 0
Study 10653925 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (control)
Number of subjects: 0
Study 8631186 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD with tailstring
Number of subjects: 22
Study 8631186 — intervention group
Group type: COMPARATOR
Intervention: IUD without tailstring
Number of subjects: 22